Boehringer Ingelheim Venture Fund

Ingelheim am Rhein, Germany
SeedSeries ASeries B+RaiseTheNorth verification research (2026-10)

Investment Thesis

BIVF is a EUR 350M evergreen corporate venture fund investing globally in early-stage biotech companies developing first-in-class, disease-modifying therapeutics across oncology, regenerative medicine, and infectious disease. The fund takes minority equity stakes with board representation, focusing on the EU, US, and China, with particular emphasis on antimicrobial and regenerative medicine innovation.

Focus Areas

Investment Stage
SeedSeries ASeries B+
Sectors
BiotechnologyFirst-in-class disease-modifying therapeuticsOncologyRegenerative medicineInfectious disease (antimicrobials)

Investment Signals

GeographyGlobal
RoleBoth
Revenue Stagepre-revenue ok
Impact MandateYes
Business ModelsIP-licensing, deep-tech

Sample Portfolio Companies

ProTgen
STRM.BIO
smartbax (follow-on)

AUM & Sources

N/A
Assets under management (estimated)
Sources
No public sources found.
Raising from Canadian VCs?Get AI-matched to your top investors in seconds.
Find My Investors →

Similar Funds

adMare BioInnovations
Vancouver, BC
SeedSeries A
FACIT Inc.
Toronto, ON
SeedSeries A
Quark Venture Inc.
Vancouver, BC
SeedSeries A
BDC Life Sciences Venture Fund
Canada
SeedSeries A

See incorrect information?

Help us keep this directory accurate and up to date.